Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P28562
UPID:
DUS1_HUMAN
Alternative names:
Dual specificity protein phosphatase hVH1; Mitogen-activated protein kinase phosphatase 1; Protein-tyrosine phosphatase CL100
Alternative UPACC:
P28562; D3DQL9; Q2V508
Background:
Dual specificity protein phosphatase 1 (DSP1), also known as Mitogen-activated protein kinase phosphatase 1 and Protein-tyrosine phosphatase CL100, plays a pivotal role in cellular processes by dephosphorylating MAP kinase MAPK1/ERK2. This action regulates the kinase's activity during the meiotic cell cycle, highlighting its critical function in cell division and signaling.
Therapeutic significance:
Understanding the role of Dual specificity protein phosphatase 1 could open doors to potential therapeutic strategies. Its involvement in key signaling pathways suggests its potential as a target in diseases where these pathways are dysregulated.